Thermo Fisher Scientific Valuation
Is TMO * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of TMO * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: TMO * (MX$9930) is trading above our estimate of fair value (MX$5452.92)
Significantly Below Fair Value: TMO * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for TMO *?
Other financial metrics that can be useful for relative valuation.
What is TMO *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$227.04b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6x |
Enterprise Value/EBITDA | 23.7x |
PEG Ratio | 3.5x |
Price to Earnings Ratio vs Peers
How does TMO *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 42.5x | ||
DHR Danaher | 47.2x | 13.5% | US$186.4b |
A Agilent Technologies | 35.9x | 9.0% | US$43.3b |
IQV IQVIA Holdings | 31x | 13.0% | US$41.7b |
LONN Lonza Group | 56x | 20.2% | CHF36.6b |
TMO * Thermo Fisher Scientific | 37.6x | 10.6% | Mex$227.0b |
Price-To-Earnings vs Peers: TMO * is good value based on its Price-To-Earnings Ratio (37.6x) compared to the peer average (42.5x).
Price to Earnings Ratio vs Industry
How does TMO *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: TMO * is expensive based on its Price-To-Earnings Ratio (37.6x) compared to the Global Life Sciences industry average (32.4x).
Price to Earnings Ratio vs Fair Ratio
What is TMO *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 37.6x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate TMO *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$9,930.00 | Mex$10,614.57 +6.9% | 4.8% | Mex$11,489.03 | Mex$9,384.69 | n/a | 25 |
May ’25 | Mex$9,760.00 | Mex$10,623.55 +8.8% | 4.8% | Mex$11,521.05 | Mex$9,410.84 | n/a | 26 |
Apr ’25 | n/a | Mex$10,095.72 0% | 5.5% | Mex$11,396.08 | Mex$8,753.26 | n/a | 26 |
Mar ’25 | Mex$9,848.06 | Mex$10,193.13 +3.5% | 5.6% | Mex$11,521.59 | Mex$8,849.67 | n/a | 25 |
Feb ’25 | Mex$9,440.00 | Mex$9,996.35 +5.9% | 5.8% | Mex$11,106.23 | Mex$8,884.98 | n/a | 23 |
Jan ’25 | Mex$9,052.27 | Mex$9,295.64 +2.7% | 9.4% | Mex$10,867.33 | Mex$7,386.39 | n/a | 25 |
Dec ’24 | Mex$8,509.35 | Mex$9,294.98 +9.2% | 8.8% | Mex$11,110.91 | Mex$7,611.41 | n/a | 23 |
Nov ’24 | Mex$7,900.00 | Mex$9,524.16 +20.6% | 9.2% | Mex$11,310.81 | Mex$7,748.35 | n/a | 23 |
Oct ’24 | Mex$8,844.40 | Mex$10,919.41 +23.5% | 6.3% | Mex$12,165.75 | Mex$9,128.70 | n/a | 24 |
Sep ’24 | Mex$9,520.40 | Mex$10,500.00 +10.3% | 6.2% | Mex$11,611.35 | Mex$8,712.70 | n/a | 24 |
Aug ’24 | Mex$9,220.26 | Mex$10,517.56 +14.1% | 6.2% | Mex$11,687.59 | Mex$8,707.09 | n/a | 25 |
Jul ’24 | Mex$8,790.00 | Mex$10,763.01 +22.4% | 7.2% | Mex$11,991.42 | Mex$8,650.95 | n/a | 24 |
Jun ’24 | Mex$9,139.00 | Mex$11,038.80 +20.8% | 7.2% | Mex$12,287.38 | Mex$8,864.47 | n/a | 23 |
May ’24 | Mex$10,004.00 | Mex$11,493.41 +14.9% | 7.2% | Mex$12,812.38 | Mex$9,113.03 | Mex$9,760.00 | 22 |
Apr ’24 | Mex$10,150.11 | Mex$12,057.90 +18.8% | 7.1% | Mex$13,211.66 | Mex$9,383.81 | n/a | 22 |
Mar ’24 | Mex$9,787.20 | Mex$12,057.90 +23.2% | 7.1% | Mex$13,211.66 | Mex$9,383.81 | Mex$9,848.06 | 22 |
Feb ’24 | Mex$10,977.78 | Mex$11,814.24 +7.6% | 8.5% | Mex$13,239.53 | Mex$9,403.61 | Mex$9,440.00 | 19 |
Jan ’24 | Mex$10,750.00 | Mex$12,070.36 +12.3% | 8.2% | Mex$13,966.24 | Mex$10,254.93 | Mex$9,052.27 | 22 |
Dec ’23 | Mex$10,747.00 | Mex$11,890.54 +10.6% | 8.5% | Mex$13,808.58 | Mex$10,139.17 | Mex$8,509.35 | 20 |
Nov ’23 | Mex$10,264.61 | Mex$12,169.71 +18.6% | 8.8% | Mex$14,167.30 | Mex$10,402.56 | Mex$7,900.00 | 20 |
Oct ’23 | Mex$10,354.17 | Mex$13,090.38 +26.4% | 7.9% | Mex$14,219.21 | Mex$10,440.68 | Mex$8,844.40 | 21 |
Sep ’23 | Mex$11,007.42 | Mex$13,166.69 +19.6% | 7.7% | Mex$14,218.78 | Mex$10,440.36 | Mex$9,520.40 | 21 |
Aug ’23 | Mex$12,057.65 | Mex$13,483.06 +11.8% | 7.9% | Mex$14,574.63 | Mex$10,701.65 | Mex$9,220.26 | 20 |
Jul ’23 | Mex$10,940.00 | Mex$12,949.00 +18.4% | 8.3% | Mex$14,084.57 | Mex$10,270.00 | Mex$8,790.00 | 20 |
Jun ’23 | Mex$10,895.66 | Mex$13,250.51 +21.6% | 7.7% | Mex$14,277.60 | Mex$10,410.75 | Mex$9,139.00 | 20 |
May ’23 | Mex$11,325.81 | Mex$13,721.14 +21.1% | 8.3% | Mex$14,711.54 | Mex$10,625.00 | Mex$10,004.00 | 21 |
Analyst Forecast: Target price is less than 20% higher than the current share price.